Biotech Values

[DewDiligence]

How do you think the FDA will view this strategy?

I presume that GILD’s unorthodox submission sequence is what the FDA itself wants, so I do not expect a problem from the FDA. However, the sequencing could be confusing for the people on the advisory committee, which might make a difference if the vote turns out to be close.

I didn't listen to the call.

If not from today’s CC, how did you know? (It’s not mentioned in the PR.)